NASDAQ:UBX

Unity Biotechnology Competitors

$5.61
+0.14 (+2.56 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.50
Now: $5.61
$5.77
50-Day Range
$5.47
MA: $6.48
$7.61
52-Week Range
$2.72
Now: $5.61
$15.44
Volume363,958 shs
Average Volume748,858 shs
Market Capitalization$306.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.36

Competitors

Unity Biotechnology (NASDAQ:UBX) Vs. FDMT, CNTB, PHVS, BOLT, GRCL, and ITOS

Should you be buying UBX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Unity Biotechnology, including 4D Molecular Therapeutics (FDMT), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), Pharvaris B.V. (PHVS), Bolt Biotherapeutics (BOLT), Gracell Biotechnologies (GRCL), and iTeos Therapeutics (ITOS).

4D Molecular Therapeutics (NASDAQ:FDMT) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Unity Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
Unity BiotechnologyN/AN/AN/A($1.88)-2.98

Analyst Ratings

This is a summary of current ratings and target prices for 4D Molecular Therapeutics and Unity Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
Unity Biotechnology14001.80

4D Molecular Therapeutics presently has a consensus target price of $45.50, suggesting a potential upside of 20.75%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Unity Biotechnology.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares 4D Molecular Therapeutics and Unity Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
Unity BiotechnologyN/AN/AN/A

Summary

4D Molecular Therapeutics beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Connect Biopharma Holdings Limited American Depositary Shares (NASDAQ:CNTB) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/AN/AN/A
Unity BiotechnologyN/AN/AN/A($1.88)-2.98

Analyst Ratings

This is a summary of current ratings and target prices for Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma Holdings Limited American Depositary Shares00303.00
Unity Biotechnology14001.80

Connect Biopharma Holdings Limited American Depositary Shares presently has a consensus target price of $29.50, suggesting a potential upside of 69.05%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given Connect Biopharma Holdings Limited American Depositary Shares' stronger consensus rating and higher probable upside, equities research analysts plainly believe Connect Biopharma Holdings Limited American Depositary Shares is more favorable than Unity Biotechnology.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Connect Biopharma Holdings Limited American Depositary Shares and Unity Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect Biopharma Holdings Limited American Depositary SharesN/AN/AN/A
Unity BiotechnologyN/AN/AN/A

Summary

Connect Biopharma Holdings Limited American Depositary Shares beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Pharvaris B.V. and Unity Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
Unity Biotechnology14001.80

Pharvaris B.V. presently has a consensus target price of $47.50, suggesting a potential upside of 60.53%. Unity Biotechnology has a consensus target price of $4.80, suggesting a potential downside of 14.44%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris B.V. is more favorable than Unity Biotechnology.

Profitability

This table compares Pharvaris B.V. and Unity Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
Unity BiotechnologyN/AN/AN/A

Earnings & Valuation

This table compares Pharvaris B.V. and Unity Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
Unity BiotechnologyN/AN/AN/A($1.88)-2.98

Summary

Pharvaris B.V. beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and Bolt Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Unity Biotechnology14001.80
Bolt Biotherapeutics00403.00

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. Bolt Biotherapeutics has a consensus price target of $41.00, suggesting a potential upside of 71.12%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Unity BiotechnologyN/AN/AN/A
Bolt BiotherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Unity Biotechnology and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unity BiotechnologyN/AN/AN/A($1.88)-2.98
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Bolt Biotherapeutics beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and Gracell Biotechnologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Unity Biotechnology14001.80
Gracell Biotechnologies00403.00

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. Gracell Biotechnologies has a consensus price target of $34.50, suggesting a potential upside of 166.62%. Given Gracell Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Gracell Biotechnologies is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Unity BiotechnologyN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Unity Biotechnology and Gracell Biotechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unity BiotechnologyN/AN/AN/A($1.88)-2.98
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Summary

Gracell Biotechnologies beats Unity Biotechnology on 3 of the 5 factors compared between the two stocks.

Unity Biotechnology (NASDAQ:UBX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

37.2% of Unity Biotechnology shares are held by institutional investors. Comparatively, 71.1% of iTeos Therapeutics shares are held by institutional investors. 37.3% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Unity Biotechnology and iTeos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Unity Biotechnology14001.80
iTeos Therapeutics00503.00

Unity Biotechnology currently has a consensus price target of $4.80, suggesting a potential downside of 14.44%. iTeos Therapeutics has a consensus price target of $49.40, suggesting a potential upside of 105.92%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than Unity Biotechnology.

Profitability

This table compares Unity Biotechnology and iTeos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Unity BiotechnologyN/AN/AN/A
iTeos TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Unity Biotechnology and iTeos Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unity BiotechnologyN/AN/AN/A($1.88)-2.98
iTeos TherapeuticsN/AN/AN/AN/AN/A

Summary

iTeos Therapeutics beats Unity Biotechnology on 4 of the 5 factors compared between the two stocks.


Unity Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FDMT
4D Molecular Therapeutics
1.1$37.68+5.1%$1.01 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.45+2.9%$974.01 millionN/A0.00Analyst Report
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.59+2.5%$942.15 millionN/A0.00Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.96+8.3%$870.42 millionN/A0.00Analyst Report
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.94+7.1%$848.39 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.99+4.0%$842.03 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$13.00+1.9%$829.48 millionN/A0.00Decrease in Short Interest
News Coverage
FNCH
Finch Therapeutics Group
2.0$16.66+2.0%$785.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$19.88+6.2%$626.08 millionN/A0.00Increase in Short Interest
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$21.65+17.8%$543.96 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$23.89+12.3%$543.69 millionN/A0.00Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.60+2.9%$525.37 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.54+2.0%$496.21 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.26+5.8%$451.73 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.75+2.8%$451.17 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.13+5.6%$446.09 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.17+3.8%$340.38 millionN/A0.00Gap Down
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.87+3.6%$291.75 millionN/A-2.72
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.83+3.9%$269.69 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.94+7.3%$209.16 millionN/A0.00Increase in Short Interest
LBPH
Longboard Pharmaceuticals
1.9$12.15+2.4%$205.54 millionN/A0.00Analyst Report
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.90+5.4%$159.09 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.02+5.8%$158.90 millionN/A0.00Analyst Report
VINC
Vincerx Pharma
1.0$19.05+0.6%$156.31 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$7.33+11.2%$140.73 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$7.49+2.3%$140.12 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.92+4.3%$85.26 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$14.46+6.3%$56.51 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.31+2.3%$53.37 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.90+0.8%$49.15 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29+2.1%$38.75 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.87+5.1%$33.17 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3N/AN/A$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01+12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84+4.9%$15.69 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.20+12.8%$2.47 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73+5.5%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.81+2.8%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00Increase in Short Interest
RPHM
Reneo Pharmaceuticals
0.3$12.32+0.7%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.82+0.4%$0.00N/A0.00Increase in Short Interest
VECT
VectivBio
0.0$16.65+4.9%$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.